AavantiBio and Aldevron Announce Strategic Partnership To Develop Next-Generation Gene Therapies for Rare Genetic Diseases
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
Aldevron will provide plasmids for AavantiBio’s future gene therapy programs, including the company’s neuromuscular and CNS pipeline programs. In addition, Aldevron will provide AavantiBio with plasmid supply materials for Proof-of-Concept studies (POC) to be produced within AavantiBio’s planned vector core facility, which is expected to open later this year and will supply pre-clinical and analytical material for future pipeline products. The partnership with Aldevron further enhances AavantiBio’s strategic capabilities as the company looks to develop novel gene therapies for patients with rare genetic diseases.
“This collaboration is an important milestone in AavantiBio’s evolution as we seek to advance our pipeline of gene therapy candidates which have the potential to become next-generation, life-changing genetic medicines,” said Bo Cumbo, president and chief executive officer of AavantiBio. “Partnering with Aldevron, the premier plasmid DNA manufacturer in the world, and leveraging their proven manufacturing expertise, will support AavantiBio’s pre-clinical and clinical development efforts and supports our strategic plans to bring high impact, transformational therapies to patients with rare genetic diseases.”
Learn more about AavantiBio and Aldevron Announce Strategic Partnership To Develop Next-Generation Gene Therapies for Rare Genetic Diseases.